BACKGROUND: @entity28 and associated @entity209 are related to impairments of the intestinal barrier. OBJECTIVE: We examined @entity11884 : @entity2656 (Lac: @entity1 ) permeability in @entity28 individuals with and without @entity1560 undergoing a weight-reduction program to test whether an effective weight-loss program improves gut barrier function and whether @entity28 @entity1 with or without @entity1560 differ in this function. DESIGN: Twenty-seven adult, nondiabetic individuals [mean    SD body mass index (BMI; in kg/m(2)): 43.7    5.2; 78% with moderate or severe @entity1560 ] were included in the follow-up intervention study (n = 13 by month 12). All @entity1 reduced their weight to a mean    SD BMI of 36.4    5.1 within 12 mo. We assessed barrier functions by the oral Lac: @entity1 and the fecal zonulin tests. @entity2690 resistance was assessed by the homeostatic model assessment index (HOMA), and @entity1560 by sonography and the @entity1560 index (FLI). RESULTS: The Lac: @entity1 ratio and circulating @entity650 concentration decreased during intervention from 0.080 (95% CI: 0.073, 0.093) to 0.027 (95% CI: 0.024, 0.034; P < 0.001) and from 4.2    1.4 to 2.8    1.6 pg/mL (P < 0.01), respectively. At study start, the Lac: @entity1 ratio was higher in @entity1 with moderate or severe @entity1560 than in those without any @entity1560 (P < 0.001). The Lac: @entity1 ratio tended to correlate with HOMA (   = 0.55, P = 0.052), which correlated with FLI (   = 0.75, P < 0.01). A multiple-regression analysis led to a final model explaining FLI best through BMI, waist circumference, and the Lac: @entity1 ratio. CONCLUSIONS: Intestinal permeability is increased in @entity28 @entity1 with @entity1560 compared with @entity28 @entity1 without. The increased permeability fell to within the previously reported normal range after @entity353 . The data suggest that a leaky gut barrier is linked with @entity1560 and could be a new target for future @entity1560 therapies. This trial was registered at clinicaltrials.gov as NCT01344525.

Gut permeability is related to body weight, fatty liver disease, and XXXX resistance in @entity28 individuals undergoing @entity353 .

@entity1 :: ('9606', 'Species') :: ['patients', 'Man'] @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol'] @entity650 :: ('3569', 'Gene') :: ['interleukin (IL) 6'] @entity11884 :: ('MESH:D007792', 'Chemical') :: ['lactulose'] @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese'] @entity1560 :: ('MESH:D005234', 'Disease') :: ['liver steatosis', 'steatosis', 'fatty liver'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight reduction'] @entity2690 :: ('3630', 'Gene') :: ['Insulin'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disorders']
@entity2690 :: (3630,Gene) :: ['insulin']
